Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

L Beach

Showing results (271-280 of 320) with videos related to

Pageof 32
Sort By:
Haematologica|April 16, 2013
A multivariate analysis of the relationship between response and survival among patients with higher-risk myelodysplastic syndromes treated within azacitidine or conventional care regimens in the randomized AZA-001 trialSteven D Gore, Pierre Fenaux, Valeria Santini, et al.
Cancer Chemotherapy and Pharmacology|February 10, 2020
Evaluation of the bioequivalence and food effect on the bioavailability of CC-486 (oral azacitidine) tablets in adult patients with cancerHani M Babiker, Mohammed Milhem, Joseph Aisner, et al.
Cancer Chemotherapy and Pharmacology|March 28, 2020
Correction to: Evaluation of the bioequivalence and food effect on the bioavailability of CC-486 (oral azacitidine) tablets in adult patients with cancerHani M Babiker, Mohammed Milhem, Joseph Aisner, et al.
Leukemia Research|December 24, 2013
Challenges of phase III trial design for novel treatments in diseases with no standard treatment: the AZA-001 myelodysplasia study modelPierre Fenaux, John F Seymour, Valeria Santini, et al.
Leukemia Research|August 17, 2018
CC-486 (oral azacitidine) in patients with myelodysplastic syndromes with pretreatment thrombocytopeniaGuillermo Garcia-Manero, Bart L Scott, Christopher R Cogle, et al.
Asia-Pacific Journal of Clinical Oncology|January 27, 2017
Efficacy, safety, and pharmacokinetics of subcutaneous azacitidine in Taiwanese patients with higher-risk myelodysplastic syndromesWen-Chien Chou, Su-Peng Yeh, Liang-Tsai Hsiao, et al.
British Journal of Haematology|January 29, 2014
Bone marrow hypocellularity does not affect tolerance or efficacy of azacitidine in patients with higher-risk myelodysplastic syndromesJohn F Seymour, John M Bennett, Alan F List, et al.
Pediatrics|November 3, 2005
Exposure to movie smoking: its relation to smoking initiation among US adolescentsJames D Sargent, Michael L Beach, Anna M Adachi-Mejia, et al.
Critical Reviews in Oncology/Hematology|May 11, 2010
Effects of azacitidine compared with conventional care regimens in elderly (≥ 75 years) patients with higher-risk myelodysplastic syndromesJohn F Seymour, Pierre Fenaux, Lewis R Silverman, et al.
British Journal of Haematology|March 29, 2023
Oral azacitidine modulates the bone marrow microenvironment in patients with acute myeloid leukaemia in remission: A subanalysis from the QUAZAR AML-001 trialDaniel L Menezes, Wendy L See, Alberto Risueño, et al.
Pageof 32

Showing results (271-280 of 320) with videos related to

Sort By:
Pageof 32
Haematologica|April 16, 2013
A multivariate analysis of the relationship between response and survival among patients with higher-risk myelodysplastic syndromes treated within azacitidine or conventional care regimens in the randomized AZA-001 trialSteven D Gore, Pierre Fenaux, Valeria Santini, et al.
Cancer Chemotherapy and Pharmacology|February 10, 2020
Evaluation of the bioequivalence and food effect on the bioavailability of CC-486 (oral azacitidine) tablets in adult patients with cancerHani M Babiker, Mohammed Milhem, Joseph Aisner, et al.
Cancer Chemotherapy and Pharmacology|March 28, 2020
Correction to: Evaluation of the bioequivalence and food effect on the bioavailability of CC-486 (oral azacitidine) tablets in adult patients with cancerHani M Babiker, Mohammed Milhem, Joseph Aisner, et al.
Leukemia Research|December 24, 2013
Challenges of phase III trial design for novel treatments in diseases with no standard treatment: the AZA-001 myelodysplasia study modelPierre Fenaux, John F Seymour, Valeria Santini, et al.
Leukemia Research|August 17, 2018
CC-486 (oral azacitidine) in patients with myelodysplastic syndromes with pretreatment thrombocytopeniaGuillermo Garcia-Manero, Bart L Scott, Christopher R Cogle, et al.
Asia-Pacific Journal of Clinical Oncology|January 27, 2017
Efficacy, safety, and pharmacokinetics of subcutaneous azacitidine in Taiwanese patients with higher-risk myelodysplastic syndromesWen-Chien Chou, Su-Peng Yeh, Liang-Tsai Hsiao, et al.
British Journal of Haematology|January 29, 2014
Bone marrow hypocellularity does not affect tolerance or efficacy of azacitidine in patients with higher-risk myelodysplastic syndromesJohn F Seymour, John M Bennett, Alan F List, et al.
Pediatrics|November 3, 2005
Exposure to movie smoking: its relation to smoking initiation among US adolescentsJames D Sargent, Michael L Beach, Anna M Adachi-Mejia, et al.
Critical Reviews in Oncology/Hematology|May 11, 2010
Effects of azacitidine compared with conventional care regimens in elderly (≥ 75 years) patients with higher-risk myelodysplastic syndromesJohn F Seymour, Pierre Fenaux, Lewis R Silverman, et al.
British Journal of Haematology|March 29, 2023
Oral azacitidine modulates the bone marrow microenvironment in patients with acute myeloid leukaemia in remission: A subanalysis from the QUAZAR AML-001 trialDaniel L Menezes, Wendy L See, Alberto Risueño, et al.
Pageof 32